Boston Scientific Corp. (NYSE:BSX) slipped another shareholder’s lawsuit that accused the company of concealing problems stemming from its ill-fated 2006 buyout of Guidant Corp.
Boston Scientific
BSX will pay big to the DOJ, Covidien loses bid in torcar war against AMR, Mela Sciences shares surge on FDA approval | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Boston Scientific to pay $9 million to settle U.S. Justice Dept.’s Guidant probe
Boston Scientific Corp. (NYSE:BSX) will pay $9.25 million to settle allegations that the med-tech goliath’s Guidant subsidiary overcharged federal health care programs for medical devices.
The government accused Natick, Mass.-based Boston Scientific’s Guidant subsidiary with exaggerating the reliability of its pacemakers and defibrillators and then failing to grant credits to purchasers when the devices failed while still under warranty.
BSX to pay $9.25 million to settle accusations that it overcharged federal health programs
BSX’s CEO, Bard’s bids for Clearstream, Infuse’s lawsuits , AdvCellTech’s stem cell trail, NuVasive’s spat, BSX’s narrow escape and Mako’s Wall Street love made headlines this week | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MDT wins $101 million against NuVasive, IOM’s 510(k) report panned by industry, BSX gets a pat on the back from judge in shareholder lawsuit | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Boston Scientific escapes fraud case
A federal judge in Massachusetts tossed a shareholders’ lawsuit accusing Boston Scientific Corp. (NYSE:BSX) of fraudulently concealing problems within its cardiac rhythm management division that prompted it to fire several members of its CRM sales force.
BSX details new CEO’s pay, Zoll’s CEO on stock slide, Infuse lawsuits mount for Medtronic | MassDevice.com +3
The top three medical device stories for Sept. 20, 2011.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
New Boston Scientific CEO Mahoney gets $2.25 million sign-on bonus
Boston Scientific Corp.’s (NYSE:BSX) newly appointed CEO Michael Mahoney signed on with a generous compensation package including a $2.25 million sign-on bonus in addition to his $900,000 base salary.
His offer letter, which also includes $16.7 million in long-term incentives through deferred stock and equity awards, is potentially worth nearly $20 million, according to SEC filings.
J&J’s non-compete pact drives Mahoney’s move to BSX, Wright Medical puts a new man in charge, Obama signs sweeping patent reform law | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.